226 related articles for article (PubMed ID: 32377219)
1. Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis.
Li H; Xi Y; Xin X; Tian H; Hu Y
Nutr Metab (Lond); 2020; 17():34. PubMed ID: 32377219
[TBL] [Abstract][Full Text] [Related]
2. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
Li H; Xi Y; Liu H; Xin X
Front Nutr; 2022; 9():914079. PubMed ID: 36091227
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice.
Li WC; Zhao SX; Ren WG; Zhang YG; Wang RQ; Kong LB; Zhang QS; Nan YM
Exp Ther Med; 2021 Aug; 22(2):830. PubMed ID: 34149876
[TBL] [Abstract][Full Text] [Related]
4. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
Li H; Xi Y; Xin X; Tian H; Hu Y
Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
[TBL] [Abstract][Full Text] [Related]
5. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
[TBL] [Abstract][Full Text] [Related]
6. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.
Sun L; Pang Y; Wang X; Wu Q; Liu H; Liu B; Liu G; Ye M; Kong W; Jiang C
Acta Pharm Sin B; 2019 Jul; 9(4):702-710. PubMed ID: 31384531
[TBL] [Abstract][Full Text] [Related]
7. Liver lipidomics analysis reveals the anti-obesity and lipid-lowering effects of gypnosides from heat-processed Gynostemma pentaphyllum in high-fat diet fed mice.
Xie P; Xie JB; Xiao MY; Guo M; Qi YS; Li FF; Piao XL
Phytomedicine; 2023 Jul; 115():154834. PubMed ID: 37094422
[TBL] [Abstract][Full Text] [Related]
8. Gypenosides Altered Hepatic Bile Acids Homeostasis in Mice Treated with High Fat Diet.
Lu Y; Du Y; Qin L; Wu D; Wang W; Ling L; Ma F; Ling H; Yang L; Wang C; Wang Z; Zhou X; He Y
Evid Based Complement Alternat Med; 2018; 2018():8098059. PubMed ID: 30105069
[TBL] [Abstract][Full Text] [Related]
9. Effects of heat-processed Gynostemma pentaphyllum on high-fat diet-fed mice of obesity and functional analysis on network pharmacology and molecular docking strategy.
Xie P; Guo M; Xie JB; Xiao MY; Qi YS; Duan Y; Li FF; Piao XL
J Ethnopharmacol; 2022 Aug; 294():115335. PubMed ID: 35513215
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
11. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
12. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling.
Sheng D; Zhao S; Gao L; Zheng H; Liu W; Hou J; Jin Y; Ye F; Zhao Q; Li R; Zhao N; Zhang L; Han Z; Wei L
Cell Biosci; 2019; 9():77. PubMed ID: 31548878
[TBL] [Abstract][Full Text] [Related]
13. Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis
Li H; Xi Y; Xin X; Feng Q; Hu Y
Front Pharmacol; 2023; 14():1148737. PubMed ID: 37077819
[No Abstract] [Full Text] [Related]
14. Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway.
Shen S; Wang K; Zhi Y; Shen W; Huang L
Cell Cycle; 2020 Nov; 19(22):3042-3053. PubMed ID: 33121337
[TBL] [Abstract][Full Text] [Related]
15. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
Matye DJ; Qin X; Hasan MN; Gu L; Clayton YD; Li F; Li T
Liver Res; 2022 Dec; 6(4):276-283. PubMed ID: 36819659
[TBL] [Abstract][Full Text] [Related]
16. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
[TBL] [Abstract][Full Text] [Related]
18. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
[TBL] [Abstract][Full Text] [Related]
19. [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice].
Tian X; Xiong Q; Chen L; Wen JR; Ru Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):746-755. PubMed ID: 31907123
[No Abstract] [Full Text] [Related]
20. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
